Pruet C W, Kornblut A D, Brickman C, Kaliner M A, Frank M M
Laryngoscope. 1983 Jun;93(6):749-55. doi: 10.1288/00005537-198306000-00010.
Angiodema can be frequently encountered in clinical practice, and usually represents transient areas of tissue edema and erythema. In general, lesions involve the deep dermis as well as subcutaneous or submucosal sites and can affect multiple organ systems, including the respiratory and gastrointestinal tracts. Although the underlying cause for the angioedema is frequently not known, it can result from atopy, specific antigen sensitivities, physical stimuli, as well as disorders that affect the complement cascade. These latter entities may be congenital or acquired. Pathogenesis for angioedema is generally thought to be activation of mast cells or basophils, with subsequent release of histamine and other mediator products which can induce inflammatory changes. In most patients with physical and allergic causes of angioedema, swelling can usually be treated with epinephrine, antihistamines and/or steroids. Management of the airway in such patients is usually symptomatic, although certain patients require hospitalization for supervised care. On the other hand, patients with hereditary angioedema do not often respond well to these agents. In such patients, we currently add infusions of epsilonaminocaproic acid as well as nembulized racemic epinephrine to our therapeutic regimen, but even this may not be satisfactory. At the National Institute of Allergy and Infectious Disease, endotracheal intubation is usually preferred to tracheostomy for securing a temporary airway, though certain patients may require placement of tracheostomies for better control of the airway. Patients with frequent recurrences of airway obstruction are rarely seen--even among those patients with known hereditary angioedema. However, such patients may require tracheal fenestrations to secure long-term protection of the airway. The Institute's experiences in the management of patients with angioedema are reviewed, and therapies employed are described.
血管性水肿在临床实践中较为常见,通常表现为组织水肿和红斑的短暂区域。一般来说,病变累及真皮深层以及皮下或黏膜下部位,可影响多个器官系统,包括呼吸道和胃肠道。虽然血管性水肿的潜在病因通常不明,但它可能由特应性、特定抗原敏感性、物理刺激以及影响补体级联反应的疾病引起。这些后者的情况可能是先天性的或后天获得的。血管性水肿的发病机制一般认为是肥大细胞或嗜碱性粒细胞的激活,随后释放组胺和其他介质产物,可诱导炎症变化。在大多数由物理和过敏原因引起血管性水肿的患者中,肿胀通常可用肾上腺素、抗组胺药和/或类固醇治疗。这类患者气道的管理通常是对症治疗,尽管某些患者需要住院接受监护。另一方面,遗传性血管性水肿患者对这些药物通常反应不佳。在这类患者中,我们目前在治疗方案中加入了ε-氨基己酸输注以及雾化消旋肾上腺素,但即便如此可能也不尽人意。在国立过敏和传染病研究所,为确保临时气道,通常首选气管插管而非气管切开术,不过某些患者可能需要进行气管切开术以更好地控制气道。气道梗阻频繁复发的患者很少见——即使在那些已知患有遗传性血管性水肿的患者中也是如此。然而,这类患者可能需要气管造口开窗术以确保气道的长期保护。本文回顾了该研究所对血管性水肿患者的管理经验,并描述了所采用的治疗方法。